Myocarditis
0
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Emergent BioSolutionsMB - Winnipeg
1 programACAM2000® Myopericarditis RegistryN/A1 trial
Active Trials
Rhythm PharmaceuticalsBOSTON, MA
1 programMyocarditis Causing Premature Ventricular Contractions:Insights From the MAVERIC RegistryN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Rhythm PharmaceuticalsMyocarditis Causing Premature Ventricular Contractions:Insights From the MAVERIC Registry
Emergent BioSolutionsACAM2000® Myopericarditis Registry
Clinical Trials (2)
Total enrollment: 124 patients across 2 trials
NCT05158751Rhythm PharmaceuticalsMyocarditis Causing Premature Ventricular Contractions:Insights From the MAVERIC Registry
Myocarditis Causing Premature Ventricular Contractions:Insights From the MAVERIC Registry
Start: Jan 2026Est. completion: May 2026100 patients
N/ANot Yet Recruiting
ACAM2000® Myopericarditis Registry
Start: Apr 2011Est. completion: Feb 201924 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.